Leerink Partners starts BlossomHill Therapeutics at Outperform, $36 target
Leerink Partners initiated coverage on BlossomHill Therapeutics with an Outperform rating and announced a $36.00/share price target.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.